Introduction
CRISPR-Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated protein 9) is an RNA-guided genome-editing platform derived from the adaptive immune systems of bacteria. It employs a synthetic single-guide RNA (sgRNA) to direct the Cas9 endonuclease to a precise genomic locus, where it introduces a double-strand break (DSB) to facilitate targeted gene knockout, insertion, or replacement.
Applications in Healthcare
CRISPR-Cas9 has shifted medicine from symptomatic management to curative genetic interventions:
- Treatment of Monogenic Disorders: In 2023, regulators approved Casgevy (exagamglogene autotemcel), the world's first CRISPR-based therapy. It provides a functional cure for sickle-cell anaemia and transfusion-dependent beta-thalassemia by reactivating fetal haemoglobin production.
- Next-Generation Oncology: CRISPR enables precision engineering of allogeneic, off-the-shelf CAR-T (Chimeric Antigen Receptor T-cell) therapies, knocking out native T-cell receptors and immune checkpoints to attack refractory hematological cancers.
- Point-of-Care Molecular Diagnostics: Diagnostic tools leverage Cas enzymes for rapid, low-cost detection of pathogen nucleic acids. An example is India's CSIR-developed FELUDA (FnCas9 Editor-Linked Uniform Detection Assay) test for infectious agents.
Applications in Agriculture
Unlike traditional transgenic genetically modified (GM) crops, genome editing can modify endogenous plant genes without introducing foreign genetic material:
- Abiotic Stress and Climate Resilience: Institutions like the Indian Council of Agricultural Research (ICAR) have developed genome-edited rice varieties, such as DRR Dhan 100 and Pusa DST Rice 1, engineered for drought and salinity tolerance.
- Disease Resistance: Precise knockouts of susceptibility (S) genes confer broad-spectrum resistance against devastating fungal and bacterial pathogens, such as bacterial blight and powdery mildew.
- Biofortification and Shelf-Life Enhancement: CRISPR can suppress genes responsible for post-harvest enzymatic browning or enhance the synthesis of micronutrients like zinc, iron, and provitamin A, aiding global nutrition security.
Regulatory and Bioethical Concerns
Despite transformative benefits, CRISPR-Cas9 presents distinct safety and governance challenges:
- Germline Editing and Eugenics: Altering the DNA of human embryos, gametes, or germ cells produces heritable modifications that pass down generations. As seen in the controversial 2018 He Jiankui case, this raises profound risks of unintended off-target mutations and revives bioethical concerns over designer babies.
- Regulatory Divergence: Jurisdictions vary widely in how they classify genome-edited organisms. While India's Ministry of Environment, Forest and Climate Change (MoEFCC) exempted Site-Directed Nuclease-1 (SDN-1) and SDN-2 crops from stringent GEAC scrutiny under EPA Rules 1989, other regions have applied standard, process-based GMO regulations, leading to global trade friction.
- Inequity and Prohibitive Costs: Advanced gene therapies carry multi-million dollar price tags—exemplified by Casgevy's market cost exceeding $2 million—preventing equitable access for populations in developing economies where the disease burden is highest.
- Ecological Biosafety and Gene Drives: Deploying CRISPR-based gene drives to suppress wild pest vectors carries irreversible risks of cross-species spillover and disruption of ecological food webs.
Conclusion
To harness CRISPR-Cas9 responsibly, nations must domesticate the World Health Organization's global governance framework on human genome editing while funding public-sector research to democratize clinical costs. Simultaneously, maintaining robust biosafety monitoring for edited crops will ensure technological benefits are balanced with ecological and ethical integrity.